Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab as Maintenance Treatment After Sequential Chemo-radiotherapy for Limited Stage SCLC
NCT07242547Phase 2Recruiting
- Sponsor
- Fundación GECP
- Start
- May 2026
- Primary completion
- Jun 2030
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Fundación GECP. Started May 2026; status: recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07242547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07242547.